Stocktoria
Hangzhou Tigermed Consulting Co., Ltd 300347.SZ
Hangzhou Tigermed Consulting Co., Ltd (300347.SZ) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.84% (safety: safe). FY2025 revenue was CN¥6.8B at a 13.0% net margin.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
About Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
How it ranks in Healthcare · percentile among 73 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.118 |
| Retained earnings / assets | 0.329 |
| EBIT / assets | 0.024 |
| Equity / liabilities | 5.109 |
FAQ
Is 300347.SZ financially healthy?
Hangzhou Tigermed Consulting Co., Ltd's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does 300347.SZ pay a dividend, and is it safe?
Yes. Hangzhou Tigermed Consulting Co., Ltd pays a dividend yielding about 0.84% with a 38.7% payout ratio, rated “safe” for safety.
How profitable is 300347.SZ?
In FY2025, Hangzhou Tigermed Consulting Co., Ltd had a net margin of 13.0% and a return on equity of 4.2%.
Computed from company filings · CN · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.